MDxHealth SA
MDXHHealthcareNASDAQDiagnostics & Research · Last scanned Oct 26, 2026
Scan Results
Daily timeframeMDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. With a market capitalization of $17.5M, it sits in micro-cap territory. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.
Market Cap
$17.5M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-0.48
EPS (TTM)
$-0.70
EPS (Fwd)
$-0.38
ROE
—
ROA
-9.8%
Cash
$19.2M
Total Debt
$105.8M
Free CF
-$17.4M
52W Change
-96.2%
Annual Financials
Cash vs Debt
Where MDXH stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, MDXH finished 83.02% below its 150-day moving average ($1.06) and 89.22% below its 200-day moving average ($1.67). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MDXH overbought or oversold?
At the October 20, 2026 close, MDXH's RSI(14) was 25.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
MDxHealth SA carries $105.8M in total debt against $19.2M in cash reserves — debt is roughly 5.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$17.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $37.1M (2022) to $107.9M (2025), reflecting a 191% increase over the period.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MDXH.